A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 ([KMT2A1], nucleophosmin 1 gene (NPM1), or nucleoporin alterations in Part 1 (Dose Escalation) and to further evaluate safety at the RP2D(s) of JNJ-75276617 in combination with chemotherapy in pediatric and young adult participants with relapsed/refractory acute leukemia harboring KMT2A1, NPM1, or nucleoporin alterations and safety at the RP2D(s) of JNJ-75276617 as monotherapy in a select low burden of disease cohort in Part 2 (Dose Expansion).

开始日期2025-12-26

申办/合作机构

Janssen Research & Development LLC

NCT05700448

/ Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2025-06-01

申办/合作机构

基石药业

NCT06124157

/ Recruiting临床3期IIT

An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

This phase III trial compares the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy versus dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or ABL-class Philadelphia chromosome-like (Ph-Like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib or imatinib and chemotherapy alone.

开始日期2025-05-30

申办/合作机构

National Cancer Institute

100 项与培门冬酶相关的临床结果

登录后查看更多信息

100 项与培门冬酶相关的转化医学

登录后查看更多信息

100 项与培门冬酶相关的专利（医药）

登录后查看更多信息

515

项与培门冬酶相关的文献（医药）

2025-06-04·ONCOLOGIST

Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma

Article

作者: Xiong, Jie ; Cheng, Shu ; Zhao, Wei-Li ; Yang, Hao-Xu ; Jiang, Xu-Feng ; Gao, Xiao ; Zhong, Hui-Juan ; Huang, Xin-Yun

Abstract:

Background:

The post-treatment Deauville scale (DS) and circulating Epstein-Barr virus (EBV)-DNA were used for prediction of long-term remission in natural killer/T-cell lymphoma (NKTCL). However, the baseline biomarkers still remain lacking for clinical application. Here, we hypothesized that 18F-FDG PET/CT, as a measure of total tumor burden, would be a baseline biomarker to identify high-risk NKTCL patients.

Methods:

We analyzed PET/CT data in early-stage NKTCL patients (n = 192) receiving pegaspargase-based regimens from 2 independent clinical trials. The prognostic values of radiomic markers including total lesion glycolysis (TLG), standardized uptake value, and metabolic tumor volume were evaluated in the training (n = 127) and validation cohorts (n = 65) with a median follow-up of 37 months.

Results:

Total lesion glycolysis was a prognosticator of progression-free survival (PFS) and overall survival (OS), with 86.11% and 91.30% sensitivity and 55.77% and 53.25% specificity, respectively, which outperformed the risk model based on posttreatment DS and circulating EBV-DNA (sensitivity 53.85% and specificity 54.24% for PFS, sensitivity 43.75% and specificity 52.34% for OS). Five-year PFS and OS were 92.19% and 96.82% in the low TLG group (<75 g), versus 69.46% and 77.24% in the high TLG group (≥75 g). ScRNA-seq (n = 10) and bulk RNA-seq (n = 65) data from patients in the trials both revealed that inflammatory dendritic cells, as immunosuppressive signature, were significantly infiltrated in patients with high TLG compared with patients with low TLG.

Conclusions:

Baseline TLG reflected an immunosuppressive microenvironment and was an effective radiomic marker for long-term remission in patients with early-stage NKTCL.

2025-06-01·PEDIATRIC BLOOD & CANCER

Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Article

作者: Loh, Mignon L. ; Place, Andrew E. ; Chen, Xin ; Cooper, Todd M. ; Dunbar, Fengjiao ; Badawi, Mohamed ; Forlenza, Christopher J. ; Gerber, Nicolas U. ; Unnebrink, Kristina ; Onishi, Maika ; Opferman, Joseph T. ; Karol, Seth E. ; Cario, Gunnar ; Reinhardt, Dirk ; Rubnitz, Jeffrey E. ; Vishwamitra, Deeksha ; Bourquin, Jean‐Pierre ; O'Brien, Maureen M. ; Ross, Jeremy A. ; Fraser, Christopher ; Sunkersett, Gauri ; Dunshee, Diana R.

ABSTRACT:

Background:

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical and clinical activity in ALL. Here, we report the safety and preliminary efficacy of venetoclax combined with chemotherapy in pediatric and adolescent/young adult patients with relapsed/refractory ALL.

Procedure:

This phase 1, open‐label, two‐part, multicenter study evaluated venetoclax combined with chemotherapy in pediatric and adolescent/young adult patients (<25 years of age) with relapsed/refractory ALL. The study is registered with ClinicalTrials.gov, NCT03236857.

Results:

Thirty‐one patients were treated and received venetoclax monotherapy (n = 1), venetoclax plus dexamethasone and/or vincristine and/or pegasparaginase (VXL; n = 20) or venetoclax plus cytarabine and/or etoposide and/or pegasparaginase (n = 10). Patients were heavily pretreated, with a median of 3 prior lines of therapy. The most common grade 3/4 treatment‐emergent adverse event was febrile neutropenia (55%). One fatal adverse event possibly related to venetoclax occurred. The overall response rate of treated patients was 42%, with all responding patients achieving complete remission/complete remission with incomplete marrow recovery. In biomarker‐evaluable patients, responses to venetoclax plus VXL‐based or cytarabine‐based chemotherapy were observed in patients harboring a range of genetic alterations and heterogeneous BH3 family member dependencies.

Conclusions:

Venetoclax plus VXL‐based or cytarabine‐based chemotherapy was overall well tolerated, with promising preliminary efficacy.

2025-06-01·Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma

Article

作者: van der Laan, Lars ; Kim, Miryoung ; Cassaday, Ryan D ; Lee, Madison ; Held, Lauren ; O’Connor, Shan ; Baek, Grace

Introduction:

Pegaspargase (PEG) is a key component of standard regimens for acute lymphoblastic leukemia/lymphoma (ALL) and extranodal natural killer/T-cell lymphoma (NKTCL). Emerging evidence suggests an opportunity to decrease incidence of PEG-associated toxicities with dose capping, but evidence is limited. This study aims to evaluate whether a significant difference in PEG-associated toxicities related to dosing strategy exists and to identify patient-specific or regimen-specific factors for PEG-related toxicity.

Methods:

A retrospective analysis of PEG-associated toxicities was completed in adult patients with ALL or NKTCL who received PEG within Cancer and Leukemia Group B (CALGB) 10403 or modified dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide (mSMILE) regimens at the UW Medical Center/Fred Hutchinson Cancer Center. PEG-associated toxicities that occurred through 8 weeks after PEG doses were noted.

Results:

Twenty-eight patients received dose-capped PEG, and 29 received noncapped PEG. Fewer all-grade and grade 3/4 toxicities were observed in the dose-capped cohort. Grade 3/4 toxicities observed were hepatotoxicity, hyperglycemia, hypersensitivity, and hypertriglyceridemia. In addition, fewer grade 3/4 pancreatitis and thrombosis events occurred in the dose-capped cohort. Hypertriglyceridemia and hepatotoxicity were associated with the highest cumulative incidence proportions among all toxicities.

Conclusion:

Dose capping of PEG was associated with a similar or later median onset for most toxicities, a less heterogeneic toxicity profile, and a lower recurrence of most toxicities upon PEG rechallenge compared to the non-dose-capped cohort. Standardizing PEG dose capping in the CALGB 10403 and mSMILE regimens may translate to improved tolerance compared to a historical standard of no dose capping PEG.

项与培门冬酶相关的新闻（医药）

2025-05-12

·ioncology

18-ICML·抢先看丨汇聚中国风采！第18届国际恶性淋巴瘤会议17项口头报告及30项壁报全景呈现

由瑞士肿瘤研究所基金会（IOR）主办的第18届国际恶性淋巴瘤会议（18-ICML）将于2025年6月17日至21日在瑞士卢加诺会议中心（Palazzo dei Congressi）召开。作为全球血液肿瘤学领域最具影响力的两年一度的学术盛会，本届会议预计汇聚来自全球的千余名血液学家、临床肿瘤学家、放射肿瘤学家、儿科医生、病理学家及淋巴瘤研究领域的前沿学者，共同探讨疾病机制、转化医学进展及临床诊疗创新。在本次盛会中，中国学者以丰富的学术成果为会议增光添彩，共呈现17项口头报告及30项壁报展示（截至2025年5月12日）。《肿瘤瞭望-血液时讯》特此系统梳理研究成果，旨在为临床医师及科研工作者提供学术风向标，助力我国淋巴瘤诊疗水平的提升。口头报告（ORAL）*汇报时间均为当地时间1淋巴瘤放射治疗研讨会LYMPHOMA RADIOTHERAPY WORKSHOP中文题目：现今应该采用哪种全身治疗方案？英文题目：Which systemic regimen should be used today?发言人：中山大学附属肿瘤医院蔡清清教授时间：6.17 16:15地点：Cinema Corso中文题目：现代系统性治疗背景下早期阶段的放射剂量与照射体积英文题目：Radiation doses and volumes in early stages with modern systemic therapy发言人：Shunan Qi（北京）时间：6.17 16:30地点：Cinema Corso2聚焦专场-进行中的临床试验“FOCUS ON…” SESSIONS-ONGOING TRIALS中文题目：GUIDANCE-02：一项关于遗传亚型指导的免疫化疗在弥漫大B细胞淋巴瘤中的多中心随机III期研究英文题目：GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma摘要号：OT5发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.18 17:40地点：Cinema Corso3儿童淋巴瘤PEDIATRIC LYMPHOMAS中文题目：中国T细胞淋巴母细胞淋巴瘤儿科患者中融合基因的发生频率及其临床影响英文题目：Frequency of fusion genes and their clinical impacts in Chinese pediatric patients with T cell lymphoblastic lymphoma摘要号：36发言人：高博医学（血液病）北京研究中心北京高博博仁医院医疗张永红教授时间：6.19 15:55地点：Auditorium, West Campus USI中文题目：53例复发或难治性儿童ALK阳性间变性大细胞淋巴瘤的临床分析英文题目：Clinical analysis of 53 cases of relapsed or refractory childhood ALK + anaplastic large cell lymphoma摘要号：38发言人：高博医学（血液病）北京研究中心王凯教授时间：6.19 16:15地点：Auditorium, West Campus USI4套细胞淋巴瘤MANTLE CELL LYMPHOMA中文题目：奥布替尼、来那度胺联合利妥昔单抗作为套细胞淋巴瘤一线治疗的新型三联方案：POLARIS多中心II期研究的最终结果英文题目：Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of POLARIS Multicenter Phase II Study摘要号：48发言人：天津医科大学肿瘤医院宋拯教授时间：6.19 16:15地点：Room A.bradcast in Ginema Corso5早期临床试验EARLY CLINICAL TRIALS中文题目：DZD8586在经共价或非共价BTK抑制剂及BTK降解剂治疗后的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的I/II期研究英文题目：Phase 1/2 Studies of DZD8586 in CLL/SLL Patients after Covalent or Non-covalent BTKInhibitors and BTK Degraders摘要号：146发言人：南京医科大学第一附属医院（江苏省人民医院）李建勇教授时间：6.19 17:35地点：Auditorium, West Campus USI7NK/T细胞淋巴瘤NK/T-CELL LYMPHOMA中文题目：SHR2554（一种口服性EZH2抑制剂）在复发或难治性外周T细胞淋巴瘤中的关键性研究英文题目：A Pivotal Study of SHR2554, An Oral Inhibitor Against Enhancer of Zeste Homolog 2 (EZH2), in Relapsed or Refractory (r/r) Peripheral T-cell Lymphoma (PTCL)摘要号：61发言人：北京大学肿瘤医院宋玉琴教授时间：6.20 09 :15地点：Room B,broadcast in Marquee Parco Ciani中文题目：帕博利珠单抗联合放疗治疗新诊断早期自然杀伤/T细胞淋巴瘤虚弱患者的Ⅱ期临床试验（IELSG50）英文题目：A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)摘要号：62发言人：上海交通大学医学院附属瑞金医院赵维莅教授时间：6.20 09 :30地点：Room B,broadcast in Marquee Parco Ciani中文题目：卡瑞利珠单抗联合低剂量阿帕替尼及培门冬酶后行放疗治疗新诊断Ⅰ/Ⅱ期自然杀伤/T细胞淋巴瘤：一项多中心Ⅱ期研究英文题目：Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study摘要号：63发言人：Chuanxu Liu（上海）时间：6.20 09 :45地点：Room B,broadcast in Marquee Parco Ciani8淋巴瘤研究：来自中国与欧洲的最新进展LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE中文题目：弥漫性大B细胞淋巴瘤治疗进展：中国视角亮点英文题目：Advances in DLBCL Management: Highlights from China摘要号：UCLI1发言人：哈尔滨血液病肿瘤研究所赵东陆教授时间：6.20 14:35地点：Polivalente room,East Campus USI中文题目：液体活检技术在淋巴瘤领域的最新进展英文题目：State-of-the-art of Liquid Biopsy in Lymphoma摘要号：UCLI3发言人：Meng Wu（北京）时间：6.20 14:55地点：Polivalente room,East Campus USI中文题目：中国新型药物在惰性淋巴瘤治疗中的国际应用概述英文题目：International Overview of Chinese Novel Drugs in Indolent Lymphoma摘要号：UCLI5发言人：吉林大学白求恩第一医院白鸥教授时间：6.20 16:15地点：Polivalente room,East Campus USI9新型药物NEW DRUGS中文题目：一项评估选择性 EZH2 抑制剂-XNW5004 在复发/难治性非霍奇金淋巴瘤受试者中安全性和有效性的 1/2 期研究英文题目：A Phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/ refractory non-Hodgkin lymphoma摘要号：95发言人：中国医学科学院血液病医院（中国医学科学院血液学研究所）邱录贵教授时间：6:21 10:30地点：Room A10T细胞淋巴瘤的生物学与治疗BIOLOGY AND THERAPY OF T-CELL LYMPHOMAS中文题目：他泽司他联合Amdizalisib 治疗具有不同基因组特征的复发或难治性外周T细胞淋巴瘤患者：一项Ⅱ期研究结果英文题目：Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study摘要号：163发言人：上海交通大学医学院附属瑞金医院程澍教授时间：6:21 09:55地点：Room B中文题目：林普利塞联合CHOP方案治疗新诊断外周T细胞淋巴瘤：一项单臂、开放标签、多中心Ⅰb/Ⅱ期研究（LINCH试验）英文题目：Linperlisib Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma: A Single-Arm,Open-Lable, Multi-Center Phase Ib/II Study (LINCH Trial)摘要号：165发言人：中山大学附属肿瘤医院蔡清清教授时间：6.21 10:15地点：Room B中文题目：戈利昔替尼（一种选择性JAK1抑制剂）作为一线全身治疗后外周T细胞淋巴瘤患者维持治疗的疗效更新：Ⅱ期研究（JACKPOT26）进展英文题目：Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with PTCLs after First-line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)摘要号：167发言人：浙江大学医学院附属第一医院金洁教授时间：6.21 10:35地点：Room B壁报展示（POSTER）1淋巴瘤生物学Lymphoma biology中文题目：稳定化MYCT58A突变绕过T细胞辅助作用驱动生发中心B细胞淋巴瘤发生英文题目：Stabilized MYCT58A Bypasses T-Cell Help to Fuel Germinal Center B-Cell Lymphomagenesis摘要号：171作者：Baizhi Chen2淋巴瘤遗传学Lymphoma genetics中文题目：EGR2基因突变预示接受布鲁顿酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者预后不良英文题目：EGR2 mutations Confer Poor Prognosis in Chronic Lymphocytic Leukemia Treated with Bruton Tyrosine Kinase Inhibitors摘要号：176作者：Huayuan Zhu中文题目：结外受累滤泡性淋巴瘤的临床特征与分子异质性分析英文题目：Clinical characteristics and molecular heterogeneity in Follicular Lymphoma with extranodal involvement摘要号：178作者：赵维莅3淋巴瘤分类Lymphoma classification中文题目：全基因组测序揭示三种具有不同起源细胞特征和患者预后的滤泡性淋巴瘤亚型英文题目：Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell-of-origin and patient outcomes摘要号：193作者：Weicheng Ren中文题目：多组学解析EB病毒驱动的结外NK/T细胞淋巴瘤进展中的异质性、代谢重塑及肿瘤细胞图谱英文题目：Multi-omics dissection of EBV-driven heterogeneity, metabolic remodeling, and tumor cellular landscape in ENKTL progression摘要号：195作者：梁金花4慢性淋巴细胞白血病Chronic lymphocytic leukemia中文题目：癌前生发中心B细胞的免疫监视机制研究英文题目：Immunosurveillance of Precancerous Germinal Center B Cells摘要号：202作者：LINGLING ZHANG中文题目：空间组学与单细胞多组学揭示原发性中枢神经系统淋巴瘤与弥漫大B细胞淋巴瘤的巨噬细胞异质性英文题目：Spatial and Single-Cell Multi-omics Reveal Macrophage Heterogeneity between Primary CNS Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)摘要号：206作者：Liang Hong5边缘区与淋巴浆细胞性淋巴瘤Marginal zone and lymphoplasmacytic lymphoma中文题目：奥布替尼联合奥妥珠单抗（O2方案）一线治疗边缘区淋巴瘤的疗效、安全性及合理性：前瞻性队列研究英文题目：The efficacy, safety and rationality of Orelabrutinib plus Obinutuzumab (O2) in systemic treatment-naïve marginal zone lymphoma: a prospective cohort study摘要号：255作者：Jiadai Xu6套细胞淋巴瘤Mantle Cell Lymphoma中文题目：非结节性套细胞淋巴瘤未必等同于惰性MCL：LEO队列研究的临床观察英文题目：Leukemic non-nodal mantle cell lymphoma (nnMCL) is not necessarily equivalent to indolent MCL: A report from the LEO Cohort Study.摘要号：271作者：Tony Zibo Zhuang7侵袭性B细胞淋巴瘤——一线临床试验Aggressive B-cell lymphomas-first line clinical trials中文题目：新型ZCR方案（泽布替尼、西达本胺、利妥昔单抗）±CHOP方案在双表达弥漫大B细胞淋巴瘤一线治疗中展现显著疗效英文题目：Novel ZCR (Zanubrutinib, Chidamide, Rituximab) ± CHOP Regimen Demonstrates Promising Efficacy in Frontline Treatment of Double-Expressor Diffuse Large B-Cell Lymphoma摘要号：284作者：Zhiming Li中文题目：维泊妥珠单抗、泽布替尼联合利妥昔单抗（Pola-ZR方案）治疗初治老年及虚弱DLBCL患者的疗效与安全性：前瞻性Ⅱ期临床试验英文题目：Efficacy and Safety of Polatuzumab Vedotin, Zanubrutinib and Rituximab (Pola-ZR) in Untreated Elderly and Frail DLBCL Patients: A Prospective Phase 2 Clinical Trial摘要号：285作者：Yuhong Ren8侵袭性B细胞淋巴瘤治疗结果Aggressive B-cell lymphomas outcomes中文题目：POLARIX研究5年亚组分析：亚洲未经治疗的DLBCL患者中Pola-R-CHP方案的疗效获益验证英文题目：Five-Year Analysis of an Asia Subpopulation with Previously Untreated DLBCL Confirms Pola-R-CHP Benefit on Outcomes: The POLARIX Study摘要号：288作者：宋玉琴中文题目：中国大规模真实世界研究：不同基因亚型弥漫大B细胞淋巴瘤的临床实践模式与预后差异英文题目：Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China摘要号：294作者：许彭鹏9复发/难治性侵袭性B细胞淋巴瘤：临床试验Relapsed/refractory aggressive B-cell lymphomas: clinical trials中文题目：分子亚型指导的R-MINE+X方案治疗复发/难治性弥漫大B细胞淋巴瘤：单臂开放标签多中心Ⅱ期研究英文题目：Molecular Subtype-Guided R-MINE+X Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-arm, Open-label, Multicenter Phase II Study摘要号：317作者：梁金花10中枢神经系统淋巴瘤CNS Lymphomas中文题目：MEDZ-R方案治疗新诊断原发性中枢神经系统淋巴瘤的多中心前瞻性Ⅱ期临床试验英文题目：A multi-center prospective phase II clinical trial of the MEDZ-R regimen for the treatment of newly diagnosed primary central nervous system lymphoma摘要号：332作者：li Zou中文题目：利妥昔单抗联合大剂量甲氨蝶呤及奥布替尼作为新诊断原发性中枢神经系统淋巴瘤的诱导治疗方案英文题目：Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma摘要号：333作者：Wenrong Huang中文题目：奥布替尼联合抗PD-1抗体与福莫司汀治疗新诊断原发性中枢神经系统淋巴瘤的Ⅰ/Ⅱ期研究英文题目：A Phase I/II Study of Orelabrutinib Combined with Anti-PD-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)摘要号：334作者：Wanyue Zhao11原发性纵隔淋巴瘤Primary mediastinal lymphoma中文题目：替雷利珠单抗联合R-CHOP方案治疗初治原发性纵隔大B细胞淋巴瘤：前瞻性Ⅱ期临床试验英文题目：Anti-PD-1 antibody (Tislelizumab) combined with R-CHOP for the treatment of previously untreated primary mediastinal B-cell lymphoma: A prospective phase II study摘要号：347作者：Wen Shu juan12霍奇金淋巴瘤Hodgkin Lymphoma中文题目：老年霍奇金淋巴瘤治疗格局演变与预后分析：中国15年多中心回顾性研究揭示新型疗法影响英文题目：Evolving Treatment Landscape and Outcomes in Elderly Hodgkin Lymphoma: A 15-Year Multicenter Retrospective Analysis from China Highlighting the Impact of Novel Therapies摘要号：366作者：赵培起13儿科淋巴瘤Pediatric lymphomas中文题目：中国南方真实世界研究：PD-1抗体单药及联合方案治疗儿童淋巴瘤的疗效与安全性英文题目：real world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients in South China摘要号：375作者：Jia Zhu中文题目：儿童、青少年及青年霍奇金淋巴瘤长期生存者的晚期并发症与生活质评估英文题目：Late Complications and Quality of Life in Long-Term Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma摘要号：377作者：Linnan Wu14NK/T细胞淋巴瘤NK/T-cell Lymphomas中文题目：EGF-JAK/STAT通路突变对血管免疫母细胞性T细胞淋巴瘤的预后及功能影响研究英文题目：Prognostic and Functional Impact of EGF-JAK/STAT Pathway Mutations in Angioimmunoblastic T-cell Lymphoma (AITL)摘要号：384作者：DACHUAN HUANG中文题目：全血EB病毒DNA载量在血管免疫母细胞性T细胞淋巴瘤中的预后价值分析英文题目：The prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma摘要号：385作者：Yi Zhong中文题目：阿扎胞苷联合西达本胺及CHOP方案对比CHOP方案治疗初治外周T细胞淋巴瘤的Ⅱ期研究英文题目：A phase II study of azacitidine and chidamide plus CHOP versus CHOP in previously untreated patients with peripheral T-cell lymphoma摘要号：391作者：Chong Wei中文题目：西达本胺联合阿扎胞苷、米托蒽醌脂质体及泼尼松（CAMP方案）治疗TFH来源的初治外周T细胞淋巴瘤英文题目：Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma摘要号：392作者：Huimin Liu中文题目：PD-1抑制剂信迪利单抗联合培门冬酶与安罗替尼治疗Ⅳ期NK/T细胞淋巴瘤的疗效与安全性：多中心前瞻性研究英文题目：A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody Sintilimab in Combination With Pegaspargase and Anlotinib in Stage IV NKTCL Patients摘要号：400作者：Rong Tao15多发性骨髓瘤Multiple Myeloma中文题目：塞利尼索联合硼替佐米、来那度胺及地塞米松治疗高危初治多发性骨髓瘤的单臂多中心观察性研究英文题目：A single-arm, multi-center, observational study of Selinexor combined bortezomib, lenalidomide, and dexamethasone in high-risk newly diagnosed multiple myeloma(NDMM) 摘要号：403作者：Yuping Zhong16液体活检Liquid Biopsy中文题目：动态ctDNA监测揭示的分子特征：不同基因亚型弥漫大B细胞淋巴瘤的预后价值、临床病程及克隆演化规律英文题目：Molecular features encoded in the dynamic ctDNA monitoring reveal prognostic value, different clinical courses and clone evolution for different genetic subtypes of DLBCL摘要号：422作者：梁金花17新型组合Novel compounds中文题目：泽布替尼联合来那度胺治疗复发/难治性弥漫大B细胞淋巴瘤的Ⅰ期临床研究分析英文题目：Analysis of a Phase 1 Study of Zanubrutinib (Zanu) + Lenalidomide (Len) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)摘要号：439作者：张会来18新型细胞疗法New cellular therapies中文题目：携带OX40信号的CAR-T疗法驱动CD4+T细胞克隆扩增并克服B细胞淋巴瘤免疫抑制微环境：Ⅰ期临床试验英文题目：CAR-T Therapy with OX40 Signaling Drives Clonal Expansion of CD4+ T Cells and Overcomes Immunosuppressive Microenvironment in B-Cell Lymphoma: A Phase I Trial摘要号：466作者：Ling-Shuang Sheng*因官网尚未公布详细壁报信息，可能出现错漏，敬请谅解《肿瘤瞭望-血液时讯》将全程追踪并深度解析18-ICML的学术动态与会议进展，诚邀广大血液肿瘤领域临床工作者及研究人员持续关注本刊后续报道！（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

放射疗法临床2期

2025-04-14

·生物制品圈

探秘生物制药：大肠杆菌的神奇 “制药” 之旅

摘要：自重组 DNA 技术出现以来，大肠杆菌在生物制药领域发挥了重要作用。它具有诸多优势，如遗传背景清晰、生产成本低、产量高，但也存在一些局限性，比如无法进行某些特定的蛋白质翻译后修饰。本文对大肠杆菌生产且经美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的生物制药进行了综述，涵盖了激素、酶、肽、疫苗、融合蛋白、抗体片段及其他生物制药等类别，介绍了这些药物的治疗用途、生产公司及研发进展等信息。一、大肠杆菌在生物制药中的角色20 世纪 70 年代，随着重组 DNA 技术的出现，大肠杆菌因其能高效且低成本地生产重组蛋白而备受关注。1982 年，由大肠杆菌生产的重组胰岛素获 FDA 批准，这一里程碑事件开启了生物制药的新时代，也为更多重组药物的生产奠定了基础。尽管大肠杆菌在生产复杂蛋白质时存在一定局限，如缺乏某些翻译后修饰能力，但它依然是生物制药中极具吸引力的宿主菌，其遗传特性明确，拥有多种成熟的克隆技术和表达系统（原文 Figure 1，展示在大肠杆菌中生产重组生物制药的一般方法，帮助读者理解生产流程）。二、大肠杆菌生产的各类生物制药1.激素：大肠杆菌在激素生产方面成果丰硕。1982 年，礼来公司生产的重组人胰岛素（Humulin）获 FDA 批准，用于治疗糖尿病。之后，赛诺菲 - 安万特公司生产的长效胰岛素类似物甘精胰岛素（Lantus）、礼来公司的赖脯胰岛素（Lyumjev）等多种胰岛素类似物相继获批。此外，生长激素、干扰素、甲状旁腺激素等多种激素也由大肠杆菌生产并获批用于临床治疗不同疾病。例如，生长激素用于治疗生长激素缺乏症，干扰素用于治疗多种癌症和肝炎，甲状旁腺激素用于治疗骨质疏松症和控制低钙血症等（原文 Table 1，展示经 FDA 和 EMA 批准的大肠杆菌生产的重组激素及其作用机制，使信息更直观）。当下，还有许多新型胰岛素类似物处于临床研究阶段，旨在提升疗效和控制血糖的速度。2.酶：多种治疗用酶也可由大肠杆菌生产。比如，2010 年获批用于治疗慢性痛风的培戈洛酶（Pegloticase），2012 年获批用于降低肾功能受损患者血浆中甲氨蝶呤（MTX）含量的羧肽酶（Voraxaze），2018 年获批用于治疗急性淋巴细胞白血病的培门冬酶（Calaspargase pegol）等（原文 Table 2，呈现经 FDA 和 EMA 批准的大肠杆菌生产的重组酶及其作用机制）。目前，科研人员还在评估大肠杆菌生产的酶在临床应用中的新潜力，期望开发出更有效的治疗药物。3.肽：大肠杆菌生产的肽类生物制药在多种疾病治疗中发挥着重要作用。如用于治疗急性失代偿性心力衰竭的奈西立肽（Natrecor）、治疗生长发育障碍的胰岛素样生长因子 - 1（Increlex）、治疗骨质疏松症的降钙素（Fortical）等（原文 Table 3，展示经 FDA 和 EMA 批准的大肠杆菌生产的重组肽及其作用机制）。这些肽类药物通过与特定受体结合，调节生理过程，从而发挥治疗作用。4.疫苗：在疫苗生产领域，大肠杆菌也有重要贡献。例如，中国研发的重组戊型肝炎疫苗（Hecolin）是全球首个基于病毒样颗粒的戊型肝炎疫苗，由大肠杆菌生产并于 2011 年获批。还有人乳头瘤病毒（HPV）L1 VLPs 疫苗（Cecolin）、针对马链球菌的 Strangvac 疫苗、预防肺炎球菌感染的肺炎球菌结合疫苗等，以及多种脑膜炎球菌疫苗如 Trumenba 和 Bexsero 等，均由大肠杆菌生产并获批用于人类或动物疾病的预防（原文 Table 4，列举经 FDA 和 EMA 批准的大肠杆菌生产的重组疫苗）。此外，还有一些基于大肠杆菌生产的疫苗正处于研发阶段。5.融合蛋白和抗体片段：许多融合蛋白和抗体片段类生物制药由大肠杆菌生产并获批用于治疗多种疾病。例如，用于治疗年龄相关性黄斑变性的雷珠单抗（Ranibizumab）及其生物类似药 Byooviz 和 Susvimo，治疗 HER2 阳性乳腺癌的曲妥珠单抗（虽最初在仓鼠卵巢细胞生产，但也有在大肠杆菌生产的相关研究），治疗克罗恩病和类风湿关节炎的赛妥珠单抗（Certolizumab pegol）等（原文 Table 5，展示经 FDA 和 EMA 批准的大肠杆菌生产的重组抗体和融合蛋白及其作用机制）。近年来，还有多种在研的大肠杆菌生产的抗体和融合蛋白处于不同临床研究阶段，用于治疗癌症等疾病。6.其他生物制药：除上述类别外，大肠杆菌还用于生产其他多种生物制药。如用于治疗中性粒细胞减少症的非格司亭（Filgrastim）及其聚乙二醇化形式（Neulasta），治疗软组织肉瘤的他索纳明（Beromun），治疗类风湿关节炎的阿那白滞素（Anakinra）等。这些药物在各自的治疗领域发挥着重要作用，为患者提供了有效的治疗选择。三、总结与展望大肠杆菌在生物制药领域具有重要地位，凭借其遗传背景清晰、易于操作、生产成本低和产量高等优势，生产出了众多经 FDA 和 EMA 批准的生物制药，广泛应用于多种疾病的治疗。尽管它存在无法进行某些翻译后修饰等局限性，但随着生物技术的不断发展，这些问题有望得到解决，其在生物制药中的应用潜力将进一步提升。未来，大肠杆菌生产的生物制药可能会在疾病治疗中发挥更重要的作用，占据更大的市场份额。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗微生物疗法

2024-06-03

·恒瑞医药

2024 ASCO口头报告｜恒瑞创新药卡瑞利珠单抗联合治疗NK/T细胞淋巴瘤研究结果公布

2024年美国临床肿瘤学会（ASCO）年会上，由华中科技大学同济医学院附属协和医院张利玲教授团队开展的“卡瑞利珠单抗联合培门冬酶、依托泊苷和大剂量甲氨蝶呤治疗NK/T细胞淋巴瘤患者的II期前瞻性研究(CLAMP研究)”结果入选大会口头报告。北京时间6月2日，张利玲教授报告了该研究的最新数据。研究结果表明 1 ，卡瑞利珠单抗联合培门冬酶、依托泊苷和大剂量甲氨蝶呤治疗NK/T细胞淋巴瘤患者具有良好的疗效和安全性，有望成为此类患者新的治疗选择。 CLAMP研究入选2024 ASCO大会口头报告研究背景 NK/T细胞淋巴瘤(NKTCL)是一种侵袭性非霍奇金淋巴瘤亚型，通常伴有EBV病毒感染 2 。目前尚无标准治疗方案。对于早期NKTCL，推荐采用放疗同时联合或序贯含门冬酰胺酶(Asp)的化疗方案，5年总生存率为55%-90%。对于晚期患者，推荐使用含Asp的化疗，如SMlLE方案(地塞米松+甲氨蝶呤+异环磷酰胺+左旋门冬酰胺酶+依托泊苷)，5年总生存率为30-40% 3,4 。 PD-1抑制剂已在研究中显示出对NKTCL有效。EBV感染与NKTCL密切相关，并导致JAK-STAT信号通路激活以及PD-L1/2表达增加。细胞毒性化疗药物通过多种机制刺激肿瘤特异性免疫反应，SMlLE方案对NKTCL有效但毒性大 3，4 ，因此本研究保留3种成分(甲氨蝶呤、培门冬酶和依托泊苷)，在细胞毒性治疗方案中加入PD-1抑制剂以探讨PD-1单克隆抗体卡瑞利珠单抗联合培门冬酶、依托泊苷、高剂量甲氨蝶呤(CLAMP方案)治疗NKTCL患者的疗效和安全性。研究设计这项单臂2期研究纳入NKTCL患者。患者分为两组：A组为早期(Ann Arbor分期I/II)患者；B组为晚期(Ann Arbor分期III/IV)和复发/难治性(RR)患者。A组患者行受累野放疗联合3-4个周期的CLAMP治疗，B组给予6个周期的CLAMP治疗。CLAMP方案给药如下：培门冬酶(2500U/m2 d1，最大剂量3750U)，依托泊苷(100mg/m2 d1-3)，大剂量甲氨蝶呤(HD-MTX，3g/m2 d4)，卡瑞利珠单抗(200mg d7)。在放疗后或每2个周期化疗后评估疗效，并于基线、C5D1化疗前2-3d、末次化疗后8周进行PET/CT检查。在前2年每3个月进行1次随访，之后每6个月进行1次随访。研究主要终点为客观缓解率(ORR)和完全缓解率(CRR，根据Lugano 2014标准，基于PET/CT和MRI判定)，次要终点为无进展生存期(PFS)、总生存期(OS)以及安全性。图1. 研究设计研究结果 1.患者基线 2020年7月至2022年12月共纳入41例NK/T细胞淋巴瘤患者，36例为新诊断患者，5例为复发患者。其中14例患者为中枢神经系统(CNS)侵犯高风险，伴有2-4个NKPI危险因素(Ann Arbor期III或IV期、B症状、局部淋巴结受累、乳酸脱氢酶升高)，1例合并噬血细胞综合征(HLH)。表1. 患者基线特征 2.临床疗效放疗结束时，A组ORR达到100%(19/19)，CRR为89.5%(17/19)，部分缓解(PR)率为10.5%(2/19)。表2. A组放疗结束时的疗效结果治疗结束时，所有患者CRR为87.8%(36/41)，PR率为7.3%(3/41)，ORR达95.1%(39/41)，A组患者ORR为100%(19/19)，B组患者ORR为90.9%(20/22)；B组仅有2例患者在治疗过程中出现进展。合并HLH的患者获得完全缓解，无病达12个月以上。表3. 治疗结束后的疗效结果在随访期间，没有患者发生HLH或中枢神经系统受累。中位随访时间为21个月。整个队列的2年PFS率为72.8%，A组和B组2年PFS率分别为91.7%和53.8%。2年OS率为88.0%，A组和B组2年OS率分别为91.7%和77.5%。A组和B组均未达到中位缓解持续时间。安全性方面，整体可控。图2. 2年的PFS率图3. 2年的OS率图4. 肿瘤反应与持续时间研究结论研究结果证明，卡瑞利珠单抗联合培门冬酶、依托泊苷和大剂量甲氨蝶呤(CLAMP方案)治疗NKTCL患者具有良好的疗效和安全性，并提示可减少中枢神经系统受累和HLH的发生，有望成为NK/T细胞淋巴瘤患者新的治疗选择。《“健康中国2030”规划纲要》提出“到2030年，要实现总体癌症5年生存率提高15%”的战略目标。抗肿瘤药物是癌症患者控制和治疗疾病的重要希望。作为创新型国际化制药企业，恒瑞医药长期坚持“科技为本，为人类创造健康生活”的使命，针对肿瘤等严重威胁人类生命健康的疾病开展科研攻关，已上市的16款创新药中抗肿瘤创新药占比过半。未来，恒瑞医药将继续坚持“以患者为中心”的理念，重创新，强研发，力争研制出更多的新药、好药，服务“健康中国”，惠及全球患者。参考文献： [1] Tao Liu, Liling Zhang, et al. CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.2024 ASCO Oral 7002. [2] NCCN Guidelines, Version 2.2024. [3] Qi SN, Li YX. First-line immunochemotherapy for extranodal natural killer/T cell lymphoma. Lancet Haematol. 2024;11(5):e311-e313. doi:10.1016/S2352-3026(24)00071-1 [4] Tse E, Zhao WL, Xiong J, Kwong YL. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022;15(1):74. Published 2022 Jun 3. doi:10.1186/s13045-022-01293-5 声明： 1.本新闻旨在分享学术前沿动态，仅供医疗卫生专业人士基于学术目的参阅，非广告用途。 2. 恒瑞医药不对任何药品和/或适应症作推荐。 3.本新闻中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。

ASCO会议临床结果临床2期临床1期

100 项与培门冬酶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05387	培门冬酶	L01XX24	DB00059

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
淋巴瘤	日本	Nihon Servier Co., Ltd.	2023-06-26
超敏反应	美国	Servier Pharmaceuticals LLC	2019-01-03
急性淋巴细胞白血病	美国	Servier Pharmaceuticals LLC	1994-02-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
前体B细胞急性淋巴细胞白血病	临床3期	美国	Servier Pharmaceuticals LLC	2017-03-03
前体B细胞急性淋巴细胞白血病	临床3期	加拿大	Servier Pharmaceuticals LLC	2017-03-03
前体T淋巴细胞白血病淋巴瘤	临床3期	美国	Servier Pharmaceuticals LLC	2017-03-03
前体T淋巴细胞白血病淋巴瘤	临床3期	加拿大	Servier Pharmaceuticals LLC	2017-03-03
淋巴母细胞淋巴瘤	临床2期	美国	Shire Plc	2012-06-01
淋巴母细胞淋巴瘤	临床2期	加拿大	Shire Plc	2012-06-01
复发性儿童急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发难治性急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
难治性成人急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
非霍奇金淋巴瘤	临床1期	美国	Enzon Pharmaceuticals, Inc.	2006-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CAMPUS ALL (EHA2025)	N/A	急性淋巴细胞白血病	90	PEG-ASP 1000 UI/m^2	鬱蓋壓顧艱窪廠醖醖築(製糧蓋獵餘鹽繭糧鬱鹽) = Coagulopathy occurred in 26% of cases (grade ≥3, 6%), without significant differences in the 3 groups 築鑰選鏇廠簾艱積遞願 (願壓構鬱觸製觸範艱積 ) 更多	-	2025-05-14
Caall-F01 (ASH2024)	N/A	急性淋巴细胞白血病	2,032	Pegaspargase (Arm A (two-infusion scheme))	鹹鑰膚壓鏇積鏇鬱鹽醖(餘積鑰構膚鹹鑰鏇範廠) = 觸艱鏇鏇夢膚膚廠鬱積觸積醖醖餘簾窪齋構蓋 (憲膚繭鬱醖觸餘築範鹹 )	积极	2024-12-08
				Pegaspargase (Arm B (one-infusion scheme))	鹹鑰膚壓鏇積鏇鬱鹽醖(餘積鑰構膚鹹鑰鏇範廠) = 網壓願網鹽繭願廠願願觸積醖醖餘簾窪齋構蓋 (憲膚繭鬱醖觸餘築範鹹 )
ASH2024	N/A	急性淋巴细胞白血病 \| 淋巴瘤	-	Antihistamines (H1 and H2 blockers)	獵壓淵鑰鬱鏇衊糧顧壓(構遞鹹憲鑰獵夢獵齋觸) = 鹹衊夢顧築鏇積積鏇構鏇鬱膚遞憲醖醖鏇製艱 (範糧餘壓網衊夢鑰齋顧 )	-	2024-12-08
SOHO2024	N/A	急性淋巴细胞白血病	-	Pegaspargase	範糧廠艱衊淵襯願夢膚(艱鹽選願夢繭簾築製製) = 4% during the induction phase, 1 patient during the consolidation phase 範鏇糧範鬱艱糧築壓鏇 (製遞範遞願糧齋齋遞醖 ) 更多	-	2024-09-04
				Erwinia asparaginase
NCT03792256 (CTgov)	临床1期	复发性成人急性淋巴细胞白血病 \| T细胞淋巴瘤 \| 急性白血病 ... 更多	12	ARAC (Stratum 1 With 50 mg/m^2)	醖顧襯網鏇蓋觸築壓醖 = 願獵壓獵壓蓋膚顧繭顧廠簾築製構憲願壓淵窪 (襯鏇築積選範願顧夢廠, 壓構範製遞製艱糧觸餘 ~ 衊網鹽範遞鬱觸遞齋壓) 更多	-	2024-08-16
				ARAC (Stratum PK With 50 mg/m^2)	醖顧襯網鏇蓋觸築壓醖 = 願鹹簾憲鑰製膚獵範製廠簾築製構憲願壓淵窪 (襯鏇築積選範願顧夢廠, 廠淵廠鹹顧襯鏇築鹹製 ~ 餘齋鑰憲壓網膚鹽膚構) 更多
ENDO2024	N/A	巩固 \| 维持	2	Pegaspargase (Patient 1)	淵遞鬱觸襯廠憲艱蓋簾(顧鑰鬱簾願襯築淵簾窪) = he presented with abdominal pain, lipase of 702 units/L, TG of 3,999 mg/dl and imaging consistent with necrotizing pancreatitis 壓鹽壓壓鹹積遞膚窪廠 (鬱製遞醖範鬱鑰構範夢 ) 更多	-	2024-06-01
CALBG 10403 (ASCO2024)	N/A	急性淋巴细胞白血病	49	PEG dose ≤ 500 IU/m2	膚觸顧鏇衊壓製顧鑰繭(構構淵築鏇醖鹹繭願選) = 鑰積壓蓋網顧製獵餘觸淵襯鹹鏇憲鬱積淵鬱獵 (觸膚選積廠繭鑰繭遞壓 )	积极	2024-05-24
LAL1913CAMPUS ALL MULTICENTER STUDY (EHA2024) 人工标引	临床4期	费城染色体阴性急性淋巴细胞白血病	421	Pegaspargase	繭襯網憲齋艱淵繭範廠(願鹽鑰壓簾憲餘選艱鏇) = 鬱遞遞鬱獵顧餘襯網襯鹹衊鬱醖夢繭憲鬱餘襯 (廠鏇壓簾築憲鑰範鹹網 ) 更多	积极	2024-05-14
				Pegaspargaseogram inspired to the GIMEMA LAL1913 clinical trial (Allogeneic stem cell transplantation (HSCT))	繭襯網憲齋艱淵繭範廠(願鹽鑰壓簾憲餘選艱鏇) = 襯艱蓋夢積築蓋遞蓋膚鹹衊鬱醖夢繭憲鬱餘襯 (廠鏇壓簾築憲鑰範鹹網 ) 更多
EHA2024	N/A	白血病	13	PEG-ASP + Vincristine-Daunorubicin-Steroid based induction	構壓廠網齋鹹築繭廠觸(積齋醖遞艱鏇製願醖夢) = 鹽衊齋觸鬱鏇衊遞顧鏇繭鑰淵簾鬱齋廠鹹鑰獵 (憲繭範鑰衊鑰積艱遞構 )	积极	2024-05-14
				PEG-ASPARAGINASE (B ALL patients)	憲簾觸膚製窪觸觸製蓋(壓選築選簾構窪願鏇網) = 願願積鑰淵顧夢窪憲鏇窪壓廠築衊鹹遞蓋淵鹽 (窪顧簾襯繭糧齋襯窪鏇 )
NCT04127227 (SPIRIT, Pubmed) 人工标引	临床2期	结外NK-T细胞淋巴瘤一线 PD-1	34	Sintilimab + pegaspargaseoxaliplatin	醖醖繭選網蓋夢築淵齋(願餘憲膚鏇艱壓選積壓) = 夢壓鏇顧築範選鬱壓蓋鑰鹽鏇鑰糧淵壓獵壓網 (鹹糧範製憲鏇鹹築窪鏇, 54 ~ 95) 更多	积极	2024-03-27